您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
PRO / Antibodies

PE/iF594 Anti-Mouse CD8α Antibody

PE/iF594 Anti-Mouse CD8α Antibody

英诺赛图(InnoCyto)的 PE/iF594 Anti-Mouse CD8α Antibody(克隆 53-6.7) 为大鼠源 IgG2a 单克隆抗体,靶向 CD8(别名 CD8 alpha 等),PE/iF594 标记(633 nm 红色激光激发),适用于流式细胞术。提供 25 μg、100 μg 规格,目录价 ¥1,490 起,仅供科研使用(RUO)。

生物试剂 供应商 上海英诺赛图 ↗ 型号 201027 更新 2026-11-12
参考价格区间
¥1,490
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 PE/iF594 Anti-Mouse CD8α Antibody(克隆 53-6.7) 为大鼠源 IgG2a 单克隆抗体,靶向 CD8(别名 CD8 alpha 等),PE/iF594 标记(633 nm 红色激光激发),适用于流式细胞术。提供 25 μg、100 μg 规格,目录价 ¥1,490 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

201027 | 25 μg | ¥1,490

201028 | 100 μg | ¥3,525

Product Details

Regulatory Status|RUO

Protein Concentration|Supplied at a lot-specific concentration.

Storage & Handling|The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Recommended Usage|For flow cytometric staining, it is recommended to use less than 0.3 μg of this reagent per 0.5-1.0 million cells in a 100 μL volume. Optimal reagent performance should be determined by titration for each specific application. PE/iF594 has an excitation max at 565 nm and an emission max at 603 nm.

See All Formats|Clone 53-6.7

Background Information

CD8 is a cell surface glycoprotein that plays a critical role in cellular immunity. It is most commonly expressed on cytotoxic T lymphocytes (CD8⁺ T cells), although lower levels can also be found on subsets of natural killer (NK) cells and dendritic cells.

Structurally, CD8 exists either as a homodimer of two CD8α chains (CD8αα) or, more commonly on T cells, as a heterodimer composed of CD8α and CD8β chains (CD8αβ). Each chain contains an extracellular immunoglobulin-like domain, a transmembrane region, and a short cytoplasmic tail that associates with intracellular signaling molecules. Functionally, CD8 acts as a co-receptor for the T cell receptor (TCR) during antigen recognition. Its primary ligand is major histocompatibility complex class I (MHC I), which is expressed on nearly all nucleated cells. During immune surveillance, the TCR recognizes peptide antigens presented by MHC I, while CD8 binds to a conserved region of the MHC I molecule. This interaction stabilizes the TCR-peptide-MHC complex and brings the Src-family kinase Lck into proximity with the TCR signaling machinery, thereby enhancing signal transduction and lowering the threshold for T cell activation. Once activated, CD8⁺ T cells differentiate into cytotoxic effector cells capable of directly killing infected or malignant cells. They mediate target cell death primarily through the release of perforin and granzymes, which induce apoptosis, as well as through engagement of death receptor pathways such as Fas-Fas ligand interactions. CD8⁺ T cells also secrete cytokines, including interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), which further shape immune responses and inhibit pathogen replication.

CD8⁺ T cells are essential for protection against viral infections and for immune surveillance against cancer. However, their dysregulation contributes to disease. Insufficient CD8⁺ T cell responses can result in chronic viral infections or tumor immune evasion, while excessive or misdirected activity can cause tissue damage and contribute to autoimmune diseases, such as type 1 diabetes and multiple sclerosis. In chronic infections and cancer, persistent antigen exposure can drive CD8⁺ T cell exhaustion, characterized by reduced effector function and sustained expression of inhibitory receptors.

In therapeutics, CD8⁺ T cells are central to modern immunotherapy. Cancer treatments such as immune checkpoint inhibitors aim to reinvigorate exhausted CD8⁺ T cells, while adoptive cell therapies, including CAR-T and TCR-engineered T cells, harness or enhance CD8⁺ cytotoxic activity. CD8⁺ T cell responses are also a key goal of antiviral vaccines, underscoring their importance in both disease control and therapeutic intervention.

Data Sheets

BALB/c Mouse splenocytes were stained with PE/i F594 Anti-Mouse CD8a clone 53-6.7 (color-filled histogram) or anisotype control (gray histogram).

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格25 μg
Clone53-6.7
ApplicationFlow Cytometry
ReactivityMouse
FormatPE/iF594
Target NameCD8, CD8 alpha, T8, Lyt2, Ly-2
IsotypeRat IgG2a
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein ConcentrationSupplied at a lot-specific concentration.
Excitation LaserRed Laser (633 nm)
目录价¥1,490

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). PE/iF594 Anti-Mouse CD8α Antibody(201027)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/pe-if594-anti-mouse-cd8-antibody.html.
TeleVM. (2026, November 12). PE/iF594 Anti-Mouse CD8α Antibody(201027). 产品目录. https://www.suprotek.cn/products/item/pe-if594-anti-mouse-cd8-antibody.html
@misc{biocsp_item_pe_if594_anti_mouse_cd8_antibody,
  title        = {PE/iF594 Anti-Mouse CD8α Antibody(201027)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/pe-if594-anti-mouse-cd8-antibody.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

PE/iF594 Anti-Mouse CD8α Antibody

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。